ASSESSMENT OF CIRCULATING miRNA LEVELS IN BREAST CANCER PATIENTS DEPENDING ON CLINICAL CHARACTERISTICS AND CHEMOTHERAPY.

Experimental oncology Pub Date : 2024-02-03 DOI:10.15407/exp-oncology.2023.04.451

О Harashchenko

{"title":"ASSESSMENT OF CIRCULATING miRNA LEVELS IN BREAST CANCER PATIENTS DEPENDING ON CLINICAL CHARACTERISTICS AND CHEMOTHERAPY.","authors":"О Harashchenko","doi":"10.15407/exp-oncology.2023.04.451","DOIUrl":null,"url":null,"abstract":"Background: Breast cancer (BC) stands out as the most prevalent cancer in women. The levels of miRNA expression before and after chemotherapy are considered a potential indicator for the prognosis of the disease.Aim: To study blood plasma miRNA levels in BC patients and to assess their correlation with the menopausal status, disease stage, and molecular BC subtype.Materials and methods: Blood plasma levels of 6 miRNAs (miRNA-25, miRNA-27, miRNA-155, miRNA-200, miRNA-335, and miRNA-497) were studied in 70 BC patients and 18 healthy individuals using RT-PCR.Results: miRNA-25, miRNA-335, and miRNA-497 levels were significantly higher in BC patients, while a tendency toward a decrease in the miRNA-27 and miRNA-335 levels in premenopausal patients and high miRNA-27 levels in menopausal patients was established. After neoadjuvant chemotherapy, a decrease in the miRNA-25 and miRNA-335 levels was registered.Conclusions: The results indicated that miRNA-25, miRNA-27, miRNA-335, and miRNA-497 deserve attention as markers for assessing the efficacy of treatment of BC patients.","PeriodicalId":94318,"journal":{"name":"Experimental oncology","volume":"45 4","pages":"451-456"},"PeriodicalIF":0.0000,"publicationDate":"2024-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15407/exp-oncology.2023.04.451","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Breast cancer (BC) stands out as the most prevalent cancer in women. The levels of miRNA expression before and after chemotherapy are considered a potential indicator for the prognosis of the disease.

Aim: To study blood plasma miRNA levels in BC patients and to assess their correlation with the menopausal status, disease stage, and molecular BC subtype.

Materials and methods: Blood plasma levels of 6 miRNAs (miRNA-25, miRNA-27, miRNA-155, miRNA-200, miRNA-335, and miRNA-497) were studied in 70 BC patients and 18 healthy individuals using RT-PCR.

Results: miRNA-25, miRNA-335, and miRNA-497 levels were significantly higher in BC patients, while a tendency toward a decrease in the miRNA-27 and miRNA-335 levels in premenopausal patients and high miRNA-27 levels in menopausal patients was established. After neoadjuvant chemotherapy, a decrease in the miRNA-25 and miRNA-335 levels was registered.

Conclusions: The results indicated that miRNA-25, miRNA-27, miRNA-335, and miRNA-497 deserve attention as markers for assessing the efficacy of treatment of BC patients.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

根据临床症状和化疗评估乳腺癌患者血液中的 miRNA 含量。

背景：乳腺癌（BC）是女性发病率最高的癌症。目的：研究乳腺癌患者的血浆 miRNA 水平，并评估其与绝经状态、疾病分期和分子 BC 亚型的相关性：采用RT-PCR方法研究了70名BC患者和18名健康人血浆中6种miRNA（miRNA-25、miRNA-27、miRNA-155、miRNA-200、miRNA-335和miRNA-497）的水平。结果发现：在 BC 患者中，miRNA-25、miRNA-335 和 miRNA-497 的水平明显较高，而在绝经前患者中，miRNA-27 和 miRNA-335 的水平呈下降趋势，在绝经期患者中，miRNA-27 的水平较高。新辅助化疗后，miRNA-25和miRNA-335水平有所下降：结果表明，miRNA-25、miRNA-27、miRNA-335和miRNA-497作为评估BC患者疗效的标志物值得关注。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Experimental oncology

自引率

0.00%

发文量